Diagnostic Kits/Testing new ground: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
* Field of Molecular Diagnostics is expanding from disease detection to include Prognostics (prediction of disease risk) and tests for a patients response to treatment. Lots of discoveries of new genetic targets and biomarkers enabled by genomics and proteomics. | * Field of Molecular Diagnostics is expanding from disease detection to include Prognostics (prediction of disease risk) and tests for a patients response to treatment. Lots of discoveries of new genetic targets and biomarkers enabled by genomics and proteomics. | ||
* Biomarkers may be indicators of disease as well as potential drug targets | * Biomarkers may be indicators of disease as well as potential drug targets | ||
* Molecular Diagnostic market revenue: 2001- $1.2B; 2007- $4.2B? | * Molecular Diagnostic market revenue: 2001- $1.2B; 2007- $4.2B? | ||
=Navigation= | |||
[[Category:Diagnostic_Kits]] | |||
[http://cyber.law.harvard.edu/commonsbasedresearch/Diagnostic_Kits#Resources DK Bibliography]<br> | |||
[[Diagnostic_Kits]]<br> | |||
[[Main Page]] | |||
Latest revision as of 14:49, 4 May 2010
Hoag, H., 2004. Testing new ground. Nature, 429(6992), 682-3 (http://www.ncbi.nlm.nih.gov/pubmed/15190358)
- Field of Molecular Diagnostics is expanding from disease detection to include Prognostics (prediction of disease risk) and tests for a patients response to treatment. Lots of discoveries of new genetic targets and biomarkers enabled by genomics and proteomics.
- Biomarkers may be indicators of disease as well as potential drug targets
- Molecular Diagnostic market revenue: 2001- $1.2B; 2007- $4.2B?